Cabozantinib Dose Skipping as an Alternative to Dose Reductions
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The goal of this study is to determine if an alternative cabozantinib dosing regimens results in a similar drug exposure compared to the standard regimens in patients with metastatic renal cell carcinoma (mRCC). All dosages of cabozantinib (20 ,40, 60mg) have the same price, and cabozantinib is eliminated very slowly by the body. This means that using fewer tablets could potentially lead to cost savings, while remaining equally effective. The main questions it aims to answer are: * Is the drug exposure from our experimental regimens similar to the standard dosing regimens? * Do the experimental regimens affect the number of side effect and the patients' quality of life? Participants will: * Take cabozantinib according to either the experimental or standard dosage regimen for 4 weeks * After 4 weeks: visit the clinic to collect some blood samples and complete two questionnaires. * 1 and 3 days after this visit: visit the clinic to collect 1 blood sample. * The day after the hospital visit: switch to the other dosing regimen and according to that regimen for another 4 weeks. * After 4 weeks: visit the clinic to collect some blood samples and complete two questionnaires * 1 and 3 days after this visit: visit the clinic to collect 1 blood sample.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 18 lat
- •Potwierdzony zaawansowany rak nerki
- •Przyjmowanie cabozantinibu w dawce 20 lub 40 mg przez co najmniej 4 tygodnie
- •Dobra tolerancja leku bez poważnych efektów ubocznych
- •Ogólny stan zdrowia pozwalający na uczestnictwo w badaniu
- •Oczekiwana długość życia co najmniej 6 miesięcy
- •Zdolność do podpisania świadomej zgody
✗ Disqualifies
- •Zaburzenia przewodu pokarmowego wpływające na wchłanianie leków
- •Wcześniejsza rozległa operacja żołądka, trzustki, wątroby lub jelita
- •Stosowanie leków, które znacząco zmieniają metabolizm cabozantinibu w ciągu ostatniego miesiąca
- •Niemożność stosowania się do zalecanego zwykłego śniadania
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- August 31, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
LUMC
Leiden, Netherlands
Trial contact
Tom van der Hulle, MD PhD
Nikki Kerssemakers, MSc
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.